Albiglutide
Indication
Treatment of type 2 diabetes mellitus in adults to improve glycaemic control
Black
Brand:
Eperzan ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Albiglutide is NOT recommended for use by the NHS in Lancashire and South Cumbria. Data from the drug’s clinical trial programme indicate that albiglutide may not consistently achieve the beneficial metabolic response target set by NICE in Guideline 28 for continued prescribing of GLP‑1 agonists, defined as follows:
- a reduction of HbA1c by at least 11 mmol/mol [1.0%] and
- a weight loss of at least 3% of initial body weight in 6 months
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: